PTHL

Pheton Holdings Ltd Class A Ordinary Shares
PTHL
Market cap $53.5M

3.69 USD

-0.25

6.35%

Updated Jan 13, 3:14 PM EST

1 day

-6.35%

5 days

-9.11%

1 month

-7.75%

3 months

-29.04%

6 months

-5.38%

Year to date

-11.51%

1 year

-5.38%

5 years

-5.38%

10 years

-5.38%

About: Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

0

Funds holding %

of 6,814 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.16% more ownership

Funds ownership: 0% [Q2] → 2.16% (+2.16%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PTHL.

See Analyst Rankings

Financial journalist opinion

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, including three names that filed to raise $100 million or more. Two biotechs are scheduled to complete IPOs next Thursday, each aiming to raise $200 million.

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Pheton Holdings Ltd Announces Closing of Initial Public Offering

BEIJING, China, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the closing of its initial public offering (the “Offering”) of 2,250,000 Class A ordinary shares at a public offering price of $4.00 per share, for total gross proceeds of $9 million, before deducting underwriting discounts and other related expenses.

Pheton Holdings Ltd Announces Closing of Initial Public Offering

Pheton Holdings Ltd Announces Pricing of Initial Public Offering

BEIJING, China, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the pricing of its initial public offering (the “Offering”) of 2,250,000 Class A ordinary shares at a public offering price of $4.00 per Class A ordinary share, for total gross proceeds of $9 million, before deducting underwriting discounts and other related expenses. In addition, Pheton has granted the underwriters a 45-day option to purchase up to an additional 337,500 Class A ordinary shares at the public offering price, less underwriting discounts. The shares are expected to begin trading on the Nasdaq Capital Market on September 5, 2024, under the ticker symbol “PTHL.” The offering is expected to close on September 6, 2024, subject to satisfaction of customary closing conditions.

Pheton Holdings Ltd Announces Pricing of Initial Public Offering

See News Rankings

Charts implemented using Lightweight Charts™